Clinical trialsCompany release

Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma

🇺🇸 Inhibrx Biosciences, Inc. (INBX) · Tue 17 Nov 2026

Updated Phase 1/2 expansion data show a 62.7% ORR and 6.0-month median PFS in 51 evaluable patients, with FDA discussions planned.

Inhibrx Biosciences released updated Phase 1/2 expansion data on 17 November 2026 for ozekibart (INBRX-109), a tetravalent DR5 agonist, combined with irinotecan and temozolomide in relapsed or refractory Ewing sarcoma.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Inhibrx Biosciences, Inc. ↗

Article written by VigiEye from the official source (Inhibrx Biosciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.